Search Results - "BUCHHOLZ, Erika"

  • Showing 1 - 10 results of 10
Refine Results
  1. 1
  2. 2

    Promoter methylation of RASSF1A, RARβ and DAPK predict poor prognosis of patients with malignant mesothelioma by Fischer, Jürgen R., Ohnmacht, Ute, Rieger, Norman, Zemaitis, Marius, Stoffregen, Clemens, Kostrzewa, Michael, Buchholz, Erika, Manegold, Christian, Lahm, Harald

    Published in Lung cancer (Amsterdam, Netherlands) (01-10-2006)
    “…Hypermethylation occurs frequently in neoplastic cells and affects tumorigenesis. Malignant mesothelioma is an aggressive cancer developing in the thoracic…”
    Get full text
    Journal Article
  3. 3

    Standard versus dose-intensified chemotherapy with sequential reinfusion of hematopoietic progenitor cells in small cell lung cancer patients with favorable prognosis by Buchholz, Erika, Manegold, Christian, Pilz, Lothar, Thatcher, Nick, Drings, Peter

    Published in Journal of thoracic oncology (01-01-2007)
    “…The combination of ifosfamide, carboplatin, and etoposide (ICE) is highly effective in treating small cell lung cancer (SCLC). Myelosuppression resulting in…”
    Get more information
    Journal Article
  4. 4
  5. 5

    Gefitinib Monotherapy in Chemotherapy-Naive Patients with Inoperable Stage III/IV Non-Small-Cell Lung Cancer by Reck, Martin, Buchholz, Erika, Schott-von-Römer, Kathrin, Krützfeldt, Katrin, Gatzemeier, Ulrich, Manegold, Christian

    Published in Clinical lung cancer (01-05-2006)
    “…Gefitinib is an orally active epidermal growth factor receptor tyrosine kinase inhibitor with activity in previously treated patients with advanced-stage…”
    Get full text
    Journal Article
  6. 6

    A Pilot Trial of Gefitinib in Combination with Docetaxel in Patients with Locally Advanced or Metastatic Non–Small-Cell Lung Cancer by Manegold, Christian, Gatzemeier, Ulrich, Buchholz, Erika, Smith, Robert P., Fandi, Abderrahim

    Published in Clinical lung cancer (01-05-2005)
    “…Despite improvements in conventional treatment, patients with advanced non–small-cell lung cancer (NSCLC) have a poor prognosis, leaving a significant unmet…”
    Get full text
    Journal Article
  7. 7

    Promoter methylation of RASSF1A, RARbeta and DAPK predict poor prognosis of patients with malignant mesothelioma by Fischer, Jürgen R, Ohnmacht, Ute, Rieger, Norman, Zemaitis, Marius, Stoffregen, Clemens, Kostrzewa, Michael, Buchholz, Erika, Manegold, Christian, Lahm, Harald

    Published in Lung cancer (Amsterdam, Netherlands) (01-10-2006)
    “…Hypermethylation occurs frequently in neoplastic cells and affects tumorigenesis. Malignant mesothelioma is an aggressive cancer developing in the thoracic…”
    Get full text
    Journal Article
  8. 8

    Topotecan and etoposide as first-line therapy for extensive disease small cell lung cancer: a phase II trial of a platinum-free regimen by Reck, Martin, Groth, Gesine, Buchholz, Erika, Goetz, Elif, Gatzemeier, Ulrich, Manegold, Christian

    Published in Lung cancer (Amsterdam, Netherlands) (01-06-2005)
    “…In the treatment of extensive disease of small cell lung cancer (ED SCLC) there is an urgent need for more effective and better-tolerated drug regimens. We…”
    Get full text
    Journal Article
  9. 9
  10. 10